Tirzepatide 10mg

What Was Tirzepatide?

Tirzepatide was a major advancement in metabolic research, showing remarkable effects on weight management and blood sugar control through dual hormone receptor activation.

It worked by targeting two key gut hormones — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Together, these hormones helped regulate appetite, insulin release, and energy balance.

In research settings, Tirzepatide was studied to understand how dual incretin signaling affects obesity, type 2 diabetes, and metabolic health.

Clinical Trial Results

Tirzepatide gained global attention following the success of the SURPASS and SURMOUNT clinical trials.

In these studies, participants achieved average body-weight reductions of 15–21% over 72 weeks, with some losing even more. These results were among the best recorded for any metabolic research peptide at the time.

Researchers also found significant improvements in:

• Insulin sensitivity – how effectively the body used insulin.

• Glycemic control – balance and stability of blood sugar levels.

• HbA1c – a measure of long-term blood sugar control, improving by up to 2.3 percentage points.

• Cholesterol and triglycerides – improved lipid profiles.

• Blood pressure and heart health.

• Appetite regulation – participants felt fuller and had fewer cravings.

Together, these effects positioned Tirzepatide as one of the most successful compounds studied in dual-incretin metabolic research.

Dosing Used in Clinical Trials

In the clinical studies, Tirzepatide was given once weekly by subcutaneous injection, meaning it was injected under the skin, typically in the abdomen, thigh, or upper arm.

Researchers gradually increased the dose to help participants’ bodies adjust and reduce side effects.

The dosing schedule used in trials was:

• Started at: 2.5 mg per week for the first 4 weeks

• Then increased to: 5 mg per week

• Most participants continued at: 10 mg per week

• Some studies tested up to: 15 mg per week

These amounts reflected what was used in controlled clinical research to study safety and effectiveness.

How Tirzepatide Works

Tirzepatide activated both GLP-1 and GIP receptors, producing a combined effect that influenced several metabolic processes:

• Reduced appetite: helped participants feel full sooner and eat less.

• Enhanced insulin release: improved how the body managed glucose after meals.

• Lowered glucagon levels: decreased sugar production by the liver.

• Slowed stomach emptying: supported portion control and calorie reduction.

• Improved energy metabolism: promoted fat burning and steady blood sugar levels.

Together, these effects resulted in major, lasting improvements in weight and metabolic function.

Study Highlights

Across key studies:

• Participants lost an average of 15–21% of their body weight, with some losing more at higher doses.

• HbA1c (average blood sugar over time) improved by up to 2.3 percentage points.

• Participants reported better appetite control and fewer cravings.

• Blood pressure, cholesterol, and triglycerides improved across multiple trials.

These results established Tirzepatide as a next-generation dual-incretin compound in obesity and diabetes research.

Shipping, Storage, and Reconstitution

Tirzepatide vials were securely packaged to maintain stability during shipping.
The dry peptide powder was stored in a cool, dry place away from sunlight. For long-term storage, it was kept refrigerated or frozen.

Before research use, the powder was mixed with sterile bacteriostatic water to create a solution. Once reconstituted, the solution was stored at 2–8 °C and used within standard laboratory timelines.

For research use only – not for human or veterinary use.